Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology

Paper highlights Zabalafin Hydrogel's potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/ -- Alphyn Biologics, Inc., a clinical-stage...